Pelvital Announces Additional $2.32 Million Seed Plus Funding Boost For Flyte®
Summary
The seed plus funding will be instrumental in expediting the commercialization of Flyte, Pelvitals novel FDA-cleared revolutionary, accessible, and clinically proven treatment for stress urinary incontinence (SUI) and weakened pelvic floor muscles. "This funding will play a crucial role in accelerating our commercialization of Flyte with a strong emphasis on expanding payor coverage and enhancing clinical education and clinician awareness. "Pier 70 and I are thrilled to be part of this transformational opportunity, as Pelvitals mission aligns beautifully with our dedication to support disruptive technologies that shake up the status quo in healthcare. ""We are thrilled for the successful completion of this round as we aim to tackle the most pressing healthcare challenges," explains Oscar Moralez, Founder and Managing Partner of Boomerang Ventures. Leveraging a combination studio and venture fund, Boomerang provides the collaborative direction, deep industry expertise, and continuum of support founders need to take their innovations from ideation to market.